To ask the Secretary of State for Health, how the Government's approach to negotiating a cost-effective price for the meningococcal B vaccine Bexsero takes account of fluctuations in disease levels characteristic of that virus and the recent emergence of another strain of meningitis which may be treated using Bexsero.
The independent cost-effectiveness analysis of the use of the meningococcal B vaccine, Bexsero took account of the incidence and case fatality rates of all meningococcal disease, including meningococcal W in England during the period 2005-06 to 2011-12. The Joint Committee on Vaccination and Immunisation (JCVI) considered that these data gave a reasonable range. JCVI are the independent experts responsible for advising the Government on immunisations following due consideration of the evidence on the burden of disease, vaccine safety and efficacy and cost effectiveness.
Further information is available in Christensen H, Trotter CL, Hickman M, Edmunds WJ. Re‑evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study. BMJ 2014; 349: g5725.